Dompé Farmaceutici S.p.A. Company Profile

14:27 EDT 17th March 2018 | BioPortfolio

Dompé is one of the most dynamic, flexible and innovative set-ups on the European scene.Successful in the traditional pharmaceutical market in the treatment of respiratory and osteoarticular pathologies, Dompé has also developed its presence in the area of biotechnology with innovative drugs and services
Its objective is to give value to every phase of production, every new research project, every sort of relationship with the Doctor and the Patient.
Flexibility, quality and the capacity for constructive work make Dompé the ideal partner


Via San Martino, 12-12/a


Phone: 39 02 583831
Fax: 39 02 58300590

News Articles [16 Associated News Articles listed on BioPortfolio]

Control Capability Drives Pump Selection at Fidia Farmaceutici

A leading European manufacturer of health products is benefiting from the control capabilities of peristaltic pumps from Watson-Marlow Fluid Technology Group (WMFTG). The pumps are being used for the...

Protalix BioTherapeutics Enters into an Exclusive Ex-US Partnership with Chiesi Farmaceutici for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A protein Protalix to receive $25 million upfront, an additional up to...

Pending EC decision: CHF 5993 Chiesi Farmaceutici S.p.A., beclometasone dipropionate anhydrous / formoterol fumarate dihydrate / glycopyrronium, Opinion date: 22-Feb-2018

Kamada, Chiesi Farmaceutici Terminate Inhaled Alpha-1 Antitrypsin Therapy Deal

Kamada now maintains full, worldwide commercial rights to its inhaled AAT.

Kamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency

Following Kamada’s Recent Withdrawal of European Marketing Authorization Application, Distribution Agreement Not Currently Warranted REHOVOT, Israel, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Kamada ...

EU Panel Backs Two Triple Combo Drugs for COPD Maintenance

CHF 5993 and Trydonis, from Chiesi Farmaceutici SpA, combine a glucocorticoid, a long-acting beta-2 receptor agonist, and a long-acting muscarinic antagonist. International Approvals

Protalix gives Chiesi ex-US rights to Fabry's disease treatment

Chiesi Farmaceutici gained ex-US rights to Protalix BioTherapeutics' PRX-102, or pegunigalsidase alfa, which is in late-stage -More- 

Chiesi gets ex-US rights to Protalix's Phase III Fabry candidate

Protalix BioTherapeutics Inc. licensed Chiesi Farmaceutici SPA exclusive rights to develop and commercialize its Phase III PRX102 (pegunigalsidase alfa) for Fabry disease in all territories except the...

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Curosurf [Cornerstone Therapeutics Inc.]

CUROSURF (poractant alfa)Intratracheal Suspension

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Effect of the concentration of circulating prolactin on dairy cows' responsiveness to domperidone injection.

The objective of this study was to determine whether the responsiveness of the mammary gland to prolactin (PRL) is affected by the concentration of the hormone. After 1 pre-experimental week (d -7 t...

Molecular transformation of natural and anthropogenic dissolved organic matter under photo-irradiation in the presence of nano TiO2.

Photochemical transformation of dissolved organic matter (DOM) plays a very important role in the cycling of organic carbon in aquatic systems. Increasing release of photoactive nanoparticles such as ...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Evaluation of the Filler Performance on the Nasolabial Folds of Aliaxin® EV With and Without Lidocaine 0.3%

Evaluation of the filler performance on the nasolabial folds of Aliaxin® EV with and without lidocaine 0.3%: comparison within subjects (half face method)

Evaluation of the Re-volumizing Performance of Aliaxin (New Trademark)

Aim of the study is to evaluate the re-volumizing performance and the duration effect of the product Aliaxin (new trademark) in women aged 40-65 years with midface volume defects due to ag...

Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combina...

Early Viscosupplementation After Partial Meniscectomy: a Randomized Controlled Trial

The rational of intra-articular viscosupplementation is based on both the biological and mechanical properties of HA, which exerts positive effects on the modulation of the entire joint en...

Companies [5 Associated Companies listed on BioPortfolio]

Dompé Farmaceutici S.p.A.

Dompé is one of the most dynamic, flexible and innovative set-ups on the European scene.Successful in the traditional pharmaceutical market in the treatment of respiratory and osteoarticular patholog...

ViRexx Medical

ViRexx Medical Corp. is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and chronic viral infections. ViRexx's mos...

Chiesi Farmaceutici S.p.A.

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 ...

Mediolanum farmaceutici S.p.A


Fidia Pharma USA Inc.

Fidia Pharma USA Inc., headquartered in Parsippany, NJ, is a wholly-owned subsidiary of the multinational pharmaceutical company Fidia Farmaceutici SpA. Fidia Pharma USA is focuse...

More Information about "Dompé Farmaceutici S.p.A." on BioPortfolio

We have published hundreds of Dompé Farmaceutici S.p.A. news stories on BioPortfolio along with dozens of Dompé Farmaceutici S.p.A. Clinical Trials and PubMed Articles about Dompé Farmaceutici S.p.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Dompé Farmaceutici S.p.A. Companies in our database. You can also find out about relevant Dompé Farmaceutici S.p.A. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Corporate Database Quicklinks

Searches Linking to this Company Record